Company: LIDRW
Filing Date: 2025-01-07
Form Type: 424B5
Source: 0000947871-25-000012
Chunk: 1

Company: AEye, Inc.
Filing Date: 2025-01-07
Form: 424B5
Chunk 1
---
 file another prospectus supplement or amendment prior to making such additional
sales. This Amendment amends and/or supplements only those sections of the Prior Prospectus as listed in this Amendment, and all other
sections of the Prior Prospectus remain as is.

We are an “emerging
growth company” and “smaller reporting company” as defined under U.S. federal securities laws and are subject to reduced
public company reporting requirements. Our common stock is listed on the Nasdaq Capital Market (“Nasdaq”) under the symbol
“LIDR.” The last sale price of our common stock, as reported on Nasdaq on January 6, 2025, was $2.33 per share.

As of January 6, 2025, the aggregate market value of our outstanding shares of common stock held by non-affiliates, or public float, was determined to be $33,127,817 based on 14,834,161 shares of common stock outstanding, of which 616,214 are held by non-affiliates, and at a price of $2.33 per share, the closing price of our common stock on January 6, 2025. In no event will the aggregate market value of securities sold by us or on our behalf pursuant to General Instruction I.B.6 of Form S-3 during the 12 calendar month period immediately prior to, and including, the date of any such sale exceed one-third of the aggregate market value of our shares of common stock held by non-affiliates, so long as the aggregate market value of our common stock held by non-affiliates is less than $75,000,000. During the prior 12 calendar month period that ends on, and includes, January 6, 2025, we have sold $7,739,000 of our securities pursuant to General Instruction I.B.6 of Form S-3.

<div align='center'>______________________________________</div>

Investing in our common stock involves a high degree of risk. See the “Risk Factors” section beginning on page S-6 of the Prospectus Supplement dated September 13, 2024 and the documents incorporated by reference into this Amendment and the Prior Prospectus, as they may be amended, updated or supplemented periodically in our reports filed with the Securities and Exchange Commission, before investing in our common stock.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this Amendment or the Prior Prospectus are truthful